...
首页> 外文期刊>Radiation oncology >Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
【24h】

Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC

机译:建立RTOG 1308的剂量学依从性标准的可行性:III期随机试验,比较不能进行II-IIIB期NSCLC的光子与质子放射化学疗法后的总生存期

获取原文
           

摘要

Background To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. Methods Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms (DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-based engineering tool. Results Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than 10?% for most criteria; however, a deviation unacceptable rate of more than 20?% was computed for the planning target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters in which PSPT plans resulted in lower values than IMRT plans were: lung V5Gy (%) (34.4 in PSPT and 47.2 in IMRT); maximum spinal cord dose (31.7?Gy in PSPT and 43.5?Gy in IMRT); heart V5Gy (%) (19 in PSPT and 47 in IMRT); heart V30Gy (%) (11 in PSPT and 19 in IMRT); heart V45Gy (%) (7.8 in PSPT and 12.1 in IMRT); heart V50% (Gy) (7.1 in PSPT and 9.8 in IMRT) and mean heart dose (7.7?Gy in PSPT and 14.9?Gy in IMRT). Conclusions The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable.
机译:背景技术通过针对强度调制放射疗法(IMRT)和无源散射质子疗法(PSPT)计划进行测试,确定RTOG 1308试验的剂量学依从性标准的可行性。方法纳入26项肺部IMRT和26项质子PSPT计划。分析了目标和正常结构的剂量体积直方图(DVH)。使用基于知识的工程工具评估了IMRT计划的质量。结果达到了大多数RTOG 1308剂量标准。大多数标准的偏差不合格率均小于10%。但是,对于计划目标体积最小剂量服从标准,计算得出的偏差不可接受率超过20%。对于IMRT和PSPT计划,目标剂量的剂量参数非常接近。但是,PSPT计划导致正常结构的剂量值降低。 PSPT计划产生的值低于IMRT计划的剂量参数为:肺V 5Gy (%)(PSPT为34.4,IMRT为47.2);最大脊髓剂量(PSPT中为31.7?Gy,IMRT中为43.5?Gy);心脏V 5Gy (%)(PSPT为19,IMRT为47);心脏V 30Gy (%)(PSPT中为11,IMRT中为19);心脏V 45Gy (%)(PSPT为7.8,IMRT为12.1);心脏V 50%(Gy)(PSPT为7.1,IMRT为9.8)和平均心脏剂量(PSPT为7.7?Gy,IMRT为14.9?Gy)。结论经修订的RTOG 1308剂量学符合性标准是可行且可实现的。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号